Agenus Inc (NAS:AGEN)
$ 3.105 -0.795 (-20.38%) Market Cap: 66.98 Mil Enterprise Value: 71.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Agenus Inc at B Riley Securities Oncology Conference (Virtual) Transcript

Jan 18, 2023 / 04:30PM GMT
Release Date Price: $52.99 (-2.88%)
Mayank Mamtani
B. Riley Securities, Inc., Research Division - MD, Senior Biotech Research Analyst & Group Head of Healthcare

Good morning. We'll get started with our next company, Agenus Bio, where we have with us Chairman and CEO, Garo Armen; and Chief Medical Officer, Dr. Steven O'Day. Thanks to the team for being part of the B. Riley oncology conference, and appreciate you guys in the audience joining us. This is Mayank Mamtani, one of the senior biotech analysts on the health care research team. At any point during the fireside chat, feel free to e-mail me questions at [email protected].

So with that, Garo, Dr. O'Day, congrats on having a very productive past 12 to 18 months with the ongoing Phase I bot/bal trial, generating quite impressive data at recent medical conferences, including the ASCO GI conference starting actually today.

Questions & Answers

Mayank Mamtani
B. Riley Securities, Inc., Research Division - MD, Senior Biotech Research Analyst & Group Head of Healthcare

Before we dig into some of those data sets,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot